Enasidenib plus azacitidine for IDH2-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies the combination of enasidenib and azacitidine in people with acute myeloid leukemia (AML) that has an IDH2 gene mutation. It may help control the leukemia when prior treatments didn’t work or the disease came back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML (or a related leukemia with a myeloid component) that has come back or didn’t respond to prior treatment
- Your leukemia test shows an IDH2 gene mutation (documented in your records)
- You are generally able to carry out daily activities (ECOG 3 or less)
- Your kidneys and liver blood tests are within allowed limits, or the changes are explained by the leukemia or benign Gilbert’s disease
- You are not pregnant or breastfeeding, and you follow pregnancy prevention rules during the study and for 3 months after the last dose
- You do not have the specific leukemia subtype called acute promyelocytic leukemia (FAB M3) or the t(15;17) chromosome change
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Hear when a new Acute Biphenotypic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.